Skip to content
TrialScanner

NCT02437136

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Phase 1/Phase 2CompletedSNDXLeadMRKCollaborator

Registry record

Lead sponsor
Syndax Pharmaceuticals
Conditions
Non-Small Cell Lung Cancer; Melanoma; Mismatch Repair-Proficient Colorectal Cancer
Primary completion
Sep 29, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02437136 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02437136: Ph1b/2 Dose-Escalation Study... | TrialScanner